This is clinically relevant since the most often lung cancer is a probable CSCs - rich and -driven pathology, therefore the preferential targeting and elimination of these CSCs which are implicated in resistance to standard anticancer therapy, metastasis and recurrence, by TRPM7 silencing or Waixenicin A treatment alone or in combination with conventional anticancer therapeutics, constitute a potential right step towards the development of a more efficient anti-cancer therapeutic strategy for treatment of advance staged, metastatic, or recurrent lung cancer. Here, TRPM7 is linked to lung cancer.